{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"3"},{"groupId":"OG005","value":"4"},{"groupId":"OG006","value":"10"},{"groupId":"OG007","value":"12"},{"groupId":"OG008","value":"7"}]}],"title":"Any Non-SAE"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"1"},{"groupId":"OG005","value":"2"},{"groupId":"OG006","value":"1"},{"groupId":"OG007","value":"5"},{"groupId":"OG008","value":"3"}]}],"title":"Any SAE"}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"3"},{"groupId":"OG005","value":"4"},{"groupId":"OG006","value":"10"},{"groupId":"OG007","value":"12"},{"groupId":"OG008","value":"7"}],"units":"Participants"}],"description":"An AE is any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. SAE is defined as any untoward medical occurrence that, at any dose results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/ incapacity, is a congenital anomaly/ birth defect, other situations and is associated with liver injury or impaired liver function. The analysis was performed on All Subjects Population which included all participants who received at least one dose of study treatment.","groups":[{"description":"Eligible participants received GSK2816126 with a starting dose of 50 mg twice-weekly, as an intravenous solution for 28 days (3 weeks on/1 week off).","id":"OG000","title":"Part 1:GSK2816126 50 mg Twice-weekly"},{"description":"Eligible participants received GSK2816126 with a dose of 100 mg twice-weekly, as an intravenous solution for 28 days (3 weeks on/1 week off).","id":"OG001","title":"Part 1:GSK2816126 100 mg Twice-weekly"},{"description":"Eligible participants received GSK2816126 with a dose of 200 mg twice-weekly, as an intravenous solution for 28 days (3 weeks on/1 week off).","id":"OG002","title":"Part 1:GSK2816126 200 mg Twice-weekly"},{"description":"Eligible participants received GSK2816126 with a dose of 400 mg twice-weekly, as an intravenous solution for 28 days (3 weeks on/1 week off).","id":"OG003","title":"Part 1:GSK2816126 400 mg Twice-weekly"},{"description":"Eligible participants received GSK2816126 with a dose of 800 mg twice-weekly, as an intravenous solution for 28 days (3 weeks on/1 week off).","id":"OG004","title":"Part 1:GSK2816126 800 mg Twice-weekly"},{"description":"Eligible participants received GSK2816126 with a dose of 1200 mg twice-weekly, as an intravenous solution for 28 days (3 weeks on/1 week off).","id":"OG005","title":"Part 1:GSK2816126 1200 mg Twice-weekly"},{"description":"Eligible participants received GSK2816126 with a dose of 1800 mg twice-weekly, as an intravenous solution for 28 days (3 weeks on/1 week off).","id":"OG006","title":"Part 1:GSK2816126 1800 mg Twice-weekly"},{"description":"Eligible participants received GSK2816126 with a dose of 2400 mg twice-weekly, as an intravenous solution for 28 days (3 weeks on/1 week off).","id":"OG007","title":"Part 1:GSK2816126 2400 mg Twice-weekly"},{"description":"Eligible participants received GSK2816126 with a dose of 3000 mg twice-weekly, as an intravenous solution for 28 days (3 weeks on/1 week off).","id":"OG008","title":"Part 1:GSK2816126 3000 mg Twice-weekly"}],"paramType":"NUMBER","populationDescription":"All Subjects Population","reportingStatus":"POSTED","timeFrame":"Up to 3.2 years","title":"Part 1: Number of Participants With Serious Adverse Events (SAEs) and Non-serious Adverse Events (Non-SAEs)","type":"PRIMARY","unitOfMeasure":"Participants"}